Stay updated on Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.

Latest updates to the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference0.9%
- Check8 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check45 days agoChange DetectedThe status of a previously active entity has been updated to 'Unknown' and is now verified by Jiangsu HengRui Medicine Co., Ltd. This indicates a significant change in the operational status of the entity.SummaryDifference3%
- Check52 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check66 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference5%
- Check73 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
Stay in the know with updates to Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib vs Docetaxel in HER2 NSCLC Clinical Trial page.